
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.





